Epidemiology and Clinical Presentation of Medulloblastoma

Epidemiology

Medulloblastoma is most common in children younger than 10 years, with the highest incidence observed in the pediatric age range (0‑14 years)【1】【2】.
In the pediatric population, medulloblastoma accounts for 10‑20 % of all brain tumors and represents the most frequent malignant brain tumor in children【1】【2】.

Papilledema may be observed on fundoscopic examination, indicating raised intracranial pressure【3】.

Dysmetria (impaired coordination of movements) is a common cerebellar manifestation【3】.
Nystagmus is frequently present due to involvement of the cerebellar vermis or brainstem【1】.
Dysarthria with a scanning speech pattern can occur, reflecting cerebellar dysfunction【3】.

Back pain may signal spinal metastases associated with leptomeningeal spread【3】.

Urgent magnetic resonance imaging (MRI) of the brain is essential; clinicians should not delay MRI when medulloblastoma is suspected【3】.
MRI of both brain and spine with gadolinium contrast is mandatory at initial diagnosis to detect leptomeningeal dissemination, which is present in roughly one‑third of cases and significantly influences prognosis and treatment planning【3】.

The estimated prevalence of medulloblastoma in pediatric patients (under 15 years) in the United States is approximately 1,423 cases, with an incidence rate of 0.47 per 100,000 children aged 0-14 years 4, 5
Medulloblastoma accounts for 10-20% of all pediatric brain tumors, making it one of the most common malignant brain tumors in children 5, 6
In the United States, the total estimated prevalence across all age groups is 3,835 cases, with pediatric cases (under 15 years) comprising 1,423 of these 4

WNT-activated tumors: 10% of cases, most common in children aged 7-14 years with excellent prognosis (>90% long-term survival) 5, 6
SHH-activated tumors: 10-20% of cases, with prognosis dependent on TP53 mutation status 5, 6
Group 3 tumors: 25-35% of cases, associated with poor prognosis (20-30% 5-year survival) 5, 6
Group 4 tumors: 25-35% of cases, with better outcomes (75-90% survival rates) 5, 6

With modern multimodal therapy, approximately 75% of children with medulloblastoma achieve prolonged survival 5
Referral to specialized centers is critical given the rarity of this tumor—even academic brain tumor centers see only a small number of pediatric medulloblastoma cases annually, making expertise concentration essential for optimal outcomes 7, 4